Claudia Mauri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2280065/publications.pdf

Version: 2024-02-01

97 papers	14,566 citations	44069 48 h-index	49909 87 g-index
101 all docs	101 docs citations	101 times ranked	14060 citing authors

#	Article	IF	Citations
1	Regulatory B Cells in Experimental Mouse Models of Arthritis. Methods in Molecular Biology, 2021, 2270, 361-373.	0.9	0
2	The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5. Nature Communications, 2021, 12, 1893.	12.8	23
3	The emerging field of regulatory B cell immunometabolism. Cell Metabolism, 2021, 33, 1088-1097.	16.2	26
4	Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease. Med, 2021, 2, 864-883.e9.	4.4	43
5	Differential levels of IFNÎ± subtypes in autoimmunity and viral infection. Cytokine, 2021, 144, 155533.	3.2	12
6	Purification and Immunophenotypic Characterization of Human CD19+CD24hiCD38hi and CD19+CD24hiCD27+ B Cells. Methods in Molecular Biology, 2021, 2270, 77-90.	0.9	0
7	Novel Frontiers in Regulatory B cells. Immunological Reviews, 2021, 299, 5-9.	6.0	20
8	25-hydroxycholesterol: Gatekeeper of intestinal IgA. Immunity, 2021, 54, 2182-2185.	14.3	3
9	B Cell Activation and B Cell Tolerance. , 2020, , 171-187.		1
10	Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B Cells. Cell Metabolism, 2020, 31, 837-851.e10.	16.2	290
11	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	8.4	31
12	Aryl Hydrocarbon Receptor Contributes to the Transcriptional Program of IL-10-Producing Regulatory B Cells. Cell Reports, 2019, 29, 1878-1892.e7.	6.4	107
13	Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1140-1142.	0.9	40
14	Effector and regulatory B cells in immune-mediated kidney disease. Nature Reviews Nephrology, 2019, 15, 11-26.	9.6	85
15	Identification and Isolation of Regulatory B Cells in Mouse and Human. Methods in Molecular Biology, 2019, 1899, 55-66.	0.9	10
16	CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells. Nature Communications, 2018, 9, 684.	12.8	64
17	Low Percentage of Signal Regulatory Protein Î±/Î²+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. Frontiers in Immunology, 2018, 9, 2865.	4.8	9
18	Dysfunctional surface antigen-specific memory B cells accumulate in chronic hepatitis B infection. Journal of Hepatology, 2018, 68, S792-S793.	3.7	0

#	Article	IF	Citations
19	CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-Î±. Frontiers in Immunology, 2018, 9, 1372.	4.8	68
20	Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Annals of Oncology, 2018, 29, 2076-2084.	1.2	74
21	Monocyte NOTCH2 expression predicts IFN-Î² immunogenicity in multiple sclerosis patients. JCI Insight, 2018, 3, .	5.0	46
22	Circulating and intrahepatic antiviral B cells are defective in hepatitis B. Journal of Clinical Investigation, 2018, 128, 4588-4603.	8.2	208
23	SP0054â€...The contribution of regulatory b cells in protecting rheumatic diseases. , 2018, , .		0
24	Definitive childlessness in women with multiple sclerosis: a multicenter study. Neurological Sciences, 2017, 38, 1453-1459.	1.9	35
25	TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients. Arthritis Research and Therapy, 2017, 19, 8.	3.5	73
26	Human regulatory B cells in health and disease: therapeutic potential. Journal of Clinical Investigation, 2017, 127, 772-779.	8.2	333
27	Cytokine-Producing Effector B Cells. , 2016, , 269-274.		0
28	A clinical update on the significance of the gut microbiota in systemic autoimmunity. Journal of Autoimmunity, 2016, 74, 85-93.	6.5	122
29	A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. Immunity, 2016, 44, 683-697.	14.3	303
30	Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clinical and Experimental Immunology, 2015, 181, 385-400.	2.6	72
31	B regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10. Thrombosis and Haemostasis, 2015, 114, 835-847.	3.4	64
32	The expanding family of regulatory B cells. International Immunology, 2015, 27, 479-486.	4.0	236
33	The many faces of type I interferon in systemic lupus erythematosus. Journal of Clinical Investigation, 2015, 125, 2562-2564.	8.2	8
34	Regulatory B Cells: Origin, Phenotype, and Function. Immunity, 2015, 42, 607-612.	14.3	1,065
35	Regulatory B cells in CVID patients fail to suppress multifunctional IFN-Î³+TNF-Î±+CD4+ T cells differentiation. Clinical Immunology, 2015, 160, 292-300.	3.2	46
36	Exacerbated experimental arthritis in Wiskottâ€“Aldrich syndrome protein deficiency: Modulatory role of regulatory B cells. European Journal of Immunology, 2014, 44, 2692-2702.	2.9	22

#	Article	IF	Citations
37	Regulatory B cell Il-10 production is diminished in juvenile dermatomyositis. Pediatric Rheumatology, 2014, 12, .	2.1	1
38	Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology, 2014, 53, 1693-1703.	1.9	59
39	The Incognito Journey of a Regulatory B Cell. Immunity, 2014, 41, 878-880.	14.3	25
40	Editorial: Regulatory B Cells: Are We Really Ready to Manipulate Them for the Benefit of Patients With Autoimmune Diseases?. Arthritis and Rheumatology, 2014, 66, 1982-1983.	5.6	7
41	Cellular targets of regulatory B cell-mediated suppression. Molecular Immunology, 2014, 62, 296-304.	2.2	77
42	Editorial overview: Lymphocyte development. Current Opinion in Immunology, 2014, 27, v-vi.	5.5	2
43	B Cell Activation and B Cell Tolerance. , 2014, , 147-158.		2
44	Regulatory B cells are induced by gut microbiotaâ€“driven interleukin-1Î² and interleukin-6 production. Nature Medicine, 2014, 20, 1334-1339.	30.7	373
45	The quest for personalized B-cell depletion therapy in rheumatic disease. Arthritis Research and Therapy, 2014, 16, 116.	3.5	2
46	Interleukin-35 takes the 'B' line. Nature Medicine, 2014, 20, 580-581.	30.7	22
47	Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood, 2014, 124, 2034-2045.	1.4	178
48	Regulatory B Cells in Experimental Mouse Models of Arthritis. Methods in Molecular Biology, 2014, 1190, 183-194.	0.9	5
49	B regulatory cells are numerically but not functionally impaired in AAV. Presse Medicale, 2013, 42, 658.	1.9	0
50	Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus. Journal of Dermatological Science, 2013, 71, 22-28.	1.9	22
51	CD19 ⁺ CD24 ^{hi} CD38 ^{hi} B Cells Maintain Regulatory T Cells While Limiting T _H 1 and T _H 17 Differentiation. Science Translational Medicine, 2013, 5, 173ra23.	12.4	564
52	SP0086â€...Regulatory B cells in healthy and in patients with SLE. Annals of the Rheumatic Diseases, 2013, 71, 22.1-22.	0.9	0
53	Lipid-Antigen Presentation by CD1d+ B Cells Is Essential for the Maintenance of Invariant Natural Killer T Cells. Immunity, 2012, 36, 477-490.	14.3	174
54	Th17 cells are restrained by Treg cells via the inhibition of interleukinâ€6 in patients with rheumatoid arthritis responding to antiâ€“tumor necrosis factor antibody therapy. Arthritis and Rheumatism, 2012, 64, 3129-3138.	6.7	126

#	Article	IF	Citations
55	IL-10â€“Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection. Journal of Immunology, 2012, 189, 3925-3935.	0.8	310
56	Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Research and Therapy, 2012, 14, R32.	3.5	236
57	Immune Regulatory Function of B Cells. Annual Review of Immunology, 2012, 30, 221-241.	21.8	1,022
58	Biosprayed spleen cells integrate and function in mouse models. Analyst, The, 2011, 136, 3434.	3.5	6
59	B regulatory cells and the tumor-promoting actions of TNF-Î± during squamous carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10662-10667.	7.1	299
60	Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage IIâ€“III Breast Cancer. Annals of Surgical Oncology, 2011, 18, 2150-2157.	1.5	16
61	IL-10 secreting regulatory B cells are potent arbiters of autoimmunity in both mouse and man. Journal of Translational Medicine, 2011, 9, .	4.4	0
62	IL-12p35 Subunit Contributes to Autoimmunity by Limiting IL-27â€“Driven Regulatory Responses. Journal of Immunology, 2011, 187, 3402-3412.	0.8	21
63	Mice Lacking Endogenous IL-10â€“Producing Regulatory B Cells Develop Exacerbated Disease and Present with an Increased Frequency of Th1/Th17 but a Decrease in Regulatory T Cells. Journal of Immunology, 2011, 186, 5569-5579.	0.8	402
64	Regulation of immunity and autoimmunity by B cells. Current Opinion in Immunology, 2010, 22, 761-767.	5.5	110
65	Abnormal CTLAâ€4 function in T cells from patients with systemic lupus erythematosus. European Journal of Immunology, 2010, 40, 569-578.	2.9	50
66	CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients. Immunity, 2010, 32, 129-140.	14.3	1,382
67	Regulatory B cells in autoimmunity: developments and controversies. Nature Reviews Rheumatology, 2010, 6, 636-643.	8.0	172
68	Could the expression of CD86 and FcÎ³RIIB on B cells be functionally related and involved in driving rheumatoid arthritis?. Arthritis Research and Therapy, 2010, 12, 133.	3.5	6
69	Selective Targeting of B Cells with Agonistic Anti-CD40 Is an Efficacious Strategy for the Generation of Induced Regulatory T2-Like B Cells and for the Suppression of Lupus in MRL/lpr Mice. Journal of Immunology, 2009, 182, 3492-3502.	0.8	269
70	Is there a feudal hierarchy amongst regulatory immune cells? More than just Tregs. Arthritis Research and Therapy, 2009, 11, 237.	3.5	12
71	Restoring the balance: Harnessing regulatory T cells for therapy in rheumatoid arthritis. European Journal of Immunology, 2008, 38, 934-937.	2.9	23
72	The â€˜shortâ€™ history of regulatory B cells. Trends in Immunology, 2008, 29, 34-40.	6.8	258

#	Article	IF	Citations
73	Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19396-19401.	7.1	244
74	Signalling defects and cellular interactions (2). Lupus, 2008, 17, 247-250.	1.6	1
75	Immunoregulatory potential of T2-MZP BÂcells. Future Rheumatology, 2008, 3, 79-84.	0.2	2
76	If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine. Journal of Experimental Medicine, 2007, 204, 2249-2252.	8.5	12
77	Novel Suppressive Function of Transitional 2 B Cells in Experimental Arthritis. Journal of Immunology, 2007, 178, 7868-7878.	0.8	507
78	Antiâ€“TNF-Î± therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-Î². Journal of Experimental Medicine, 2007, 204, 33-39.	8.5	423
79	Cells of the synovium in rheumatoid arthritis. B cells. Arthritis Research and Therapy, 2007, 9, 205.	3.5	35
80	Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2006, 177, 7416-7422.	0.8	114
81	Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Seminars in Immunopathology, 2005, 26, 425-432.	4.0	57
82	Statins for Atherosclerosis â€" As Good as It Gets?. New England Journal of Medicine, 2005, 352, 73-75.	27.0	125
83	Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFÎ± Therapy. Journal of Experimental Medicine, 2004, 200, 277-285.	8.5	1,112
84	Atorvastatin Inhibits Autoreactive B Cell Activation and Delays Lupus Development in New Zealand Black/White F1 Mice. Journal of Immunology, 2004, 173, 7641-7646.	0.8	113
85	Type I IFN Protects Permissive Macrophages fromLegionella pneumophilaInfection through an IFN-Î³-Independent Pathway. Journal of Immunology, 2004, 173, 1266-1275.	0.8	77
86	Canonical pathway of nuclear factor ÂB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5634-5639.	7.1	300
87	Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. Arthritis and Rheumatism, 2003, 48, 839-845.	6.7	39
88	Prevention of Arthritis by Interleukin 10â€"producing B Cells. Journal of Experimental Medicine, 2003, 197, 489-501.	8.5	781
89	A comparative study into the mechanisms of action of antiâ€"tumor necrosis factor Î±, anti-CD4, and combined antiâ€"tumor necrosis factor Î±/anti-CD4 treatment in early collagen-induced arthritis. Arthritis and Rheumatism, 2000, 43, 638.	6.7	22
90	Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nature Medicine, 2000, 6, 673-679.	30.7	109

#	Article	IF	Citations
91	Therapeutic actions of cyclosporine and anti-tumor necrosis factor ? in collagen-induced arthritis and the effect of combination therapy. Arthritis and Rheumatism, 1998, 41, 1806-1812.	6.7	37
92	Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.. Journal of Clinical Investigation, 1998, 101, 429-441.	8.2	149
93	Suckling CD1 mice as an animal model for studies of Legionella pneumophila virulence. Journal of Medical Microbiology, 1997, 46, 647-655.	1.8	10
94	Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clinical and Experimental Immunology, 1997, 107, 507-512.	2.6	113
95	Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. Journal of Immunology, 1997, 159, 5032-41.	0.8	39
96	Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. Journal of Immunology, 1997, 159, 6253-9.	0.8	84
97	Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. European Journal of Immunology, 1996, 26, 1511-1518.	2.9	287